• Mashup Score: 0
    Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both? - 2 year(s) ago

    The concepts of antiangiogenic tumor therapy were pioneered on the assumption that the inhibition of tumor angiogenesis should lead to the complete regression of the tumor-associated vasculature and thereby hold the tumor in an avascular dormant state. Yet, clinical trials revealed limited efficacy of angiogenesis inhibitors when used as monotherapy. Instead, antiangiogenic drugs proved effective…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      #ICYMI: Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both? Written by @HellmutAugustin and @gou_koh https://t.co/IlOl8ZFO7T. #CRLandmark https://t.co/OiTc3TPLx1

  • Mashup Score: 9
    Cancer Needs a Robust “Metadata Supply Chain” to Realize the Promise of Artificial Intelligence - 2 year(s) ago

    Profound advances in computational methods, including artificial intelligence (AI), present the opportunity to use the exponentially growing volume and complexity of available cancer measurements toward data-driven personalized care. While exciting, this opportunity has highlighted the disconnect between the promise of compute and the supply of high-quality data. The current paradigm of ad-hoc…

    Source: Cancer Research
    Categories: Latest Headlines, Oncologists2
    Tweet Tweets with this article
    • Profile photo of CarlosHBarcenas
      CarlosHBarcenas

      Cancer Needs a Robust “Metadata Supply Chain” to Realize the Promise of Artificial Intelligence. Great article from ⁦@ca_chung⁩ from ⁦@MDAndersonNews⁩. Principles: observations in context, quality, provenance and data governance https://t.co/3YYawqC0nd

  • Mashup Score: 2
    BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences - 2 year(s) ago

    Cancer treatment is increasingly guided by molecular analyses designed to identify clinically actionable genomic alterations in individual patients. The discovery of BRAF mutations in human cancer, and the subsequent development and FDA authorization of selective BRAF inhibitors highlight the potential clinical impact and current limitations of precision oncology paradigms. In 2002, Brose and…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      #ICYMI - Read the latest #CRLandmark by Hanrahan and @DSolit: BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences https://t.co/m1iDvXpjrU https://t.co/bygsxMmWuC

  • Mashup Score: 0
    IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer - 2 year(s) ago

    Recent studies suggest that B cells could play an important role in the tumor microenvironment. However, the role of humoral responses in endometrial cancer remains insufficiently investigated. Using a cohort of 107 patients with different histological subtypes of endometrial carcinoma, we evaluated the role of coordinated humoral and cellular adaptive immune responses in endometrial cancer….

    Source: Cancer Research
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ara_anderson
      ara_anderson

      New paper just out in @CR_AACR with Jose Conejo-Garcia's lab, IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer https://t.co/IHibSbQA2G with help from @cgatenbee @sandhya212 #AndersonLab @MoffittResearch

  • Mashup Score: 0
    Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer - 2 year(s) ago

    The growing use of neoadjuvant chemotherapy to treat advanced stage high-grade serous ovarian cancer (HGSOC) creates an opportunity to better understand chemotherapy-induced mutational and gene expression changes. Here we performed a cohort study including 34 patients with advanced stage IIIC or IV HGSOC to assess changes in the tumor genome and transcriptome in women receiving neoadjuvant…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      Work by Javellana et al finds that AP-1 activity and SIK2 copy number amplification are induced by #chemotherapy and may represent mechanisms by which chemotherapy resistance evolves in high grade serous #OvarianCancer. https://t.co/Rf85eyRkK9 @sd_yamada https://t.co/F5V2nRDNwD

  • Mashup Score: 0
    EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd - 2 year(s) ago

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for EGFR -mutant non–small cell lung cancers (NSCLC). However, most patients develop acquired drug resistance to EGFR TKIs. HER3 is a unique pseudokinase member of the ERBB family that functions by dimerizing with other ERBB family members (EGFR and HER2) and is frequently overexpressed in…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      Antibody-drug conjugate HER3-DXd proved to be broadly effective in HER3 expressing cancers. Combined with #osimertinib it may be an effective treatment approach that should be further evaluated in EGFR mutant #NSCLC patients. https://t.co/aT5BF9u66e @science_yall https://t.co/WH6N4mEPwm

  • Mashup Score: 0
    FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance - 2 year(s) ago

    Fibroblast growth factor receptor 3 (FGFR3) is frequently activated by mutation or overexpression, and it is a validated therapeutic target in urothelial carcinoma (UC) of the bladder. However, the role and detailed molecular mechanism of FGFR3 in the immune microenvironment of bladder cancer remain largely unknown. Here, we demonstrate that inhibition of FGFR3 in FGFR3-activated bladder cancer…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      Ubiquitin ligase NEDD4 links two important molecules associated with targeted therapy and immune surveillance. This finding by Jing et al provides mechanistic rationale for immuno-targeted combination therapy for FGFR3-activated Bladder Cancer. https://t.co/JoceQ8yZAV https://t.co/7jgHNHNZ2a

  • Mashup Score: 0
    CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies - 2 year(s) ago

    Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer development and thus pose a challenge for clinical CRISPR use. Transient p53 inhibition could suppress the…

    Source: Cancer Research
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CR_AACR
      CR_AACR

      CRISPR-mediated DNA damage enriches for cells with escape mutations in a broad CRISPR p53 interactome. Jiang et al identify parameters affecting the enrichment, and show that it can be suppressed by transient inhibition of p53. https://t.co/qyrYMlqaBh @Wermeling_lab https://t.co/qKDno1gLOC

Load More